Liver Cancer

Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date

Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date

[Journal of Hepatocellular Carcinoma] This research examines tivantinib and its therapeutic profile in the management of hepatocellular carcinoma.

Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis

Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis

[OncoTargets and Therapy] This research examines the prognostic value of pretreatment serum albumin in RCC patients.

Hepatocellular Carcinoma: A Review

Hepatocellular Carcinoma: A Review

[Journal of Hepatocellular Carcinoma] This research examines the screening modalities, diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), the most common primary liver malignancy.

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

[Journal of Hepatocellular Carcinoma] This review examines the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics for the treatment of advanced hepatocellular carcinoma.

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

By

In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

By

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

By

In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.

Survival for Patients With Liver Cancer Differs by Race

By

A study of nearly 1000 patients with HCC found that black patients with the disease had a 33% greater risk of death compared with non-Hispanic whites.

Oncology Nurses Ideal for Educating Patients on Portal Vein Thrombosis

Oncology Nurses Ideal for Educating Patients on Portal Vein Thrombosis

By

Oncology nurses are in an ideal position to educate patients with gastrointestinal malignancies and PVT about risk factors, clinical presentation, complications, and treatment options to prevent further extension of the clot.

Novel Delivery Method Repurposes Existing Drug to Treat Liver Cancer

By

An interdisciplinary collaboration between prominent academic and industry investigators discovered a novel method for repositioning an FDA-approved anticancer compound so it can specifically target liver cancer tumors.

Blood Sample Offers a New Way of Detecting Cancer

Blood Sample Offers a New Way of Detecting Cancer

By

RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.

New Approach to Postsurgical Care Reduces Patient Recovery Time After Liver Resection

By

Patients undergoing oncologic liver surgeries who participated in an enhanced recovery program returned sooner to their normal life function and to adjuvant cancer therapies than patients who were treated with a traditional approach to perioperative care.

Probiotics Lower Rate of Infection Following Liver Transplant

Probiotics Lower Rate of Infection Following Liver Transplant

Results of a meta-analysis shows reduction in rate of infection and shorter length of hospital stay with receipt of prebiotics and probiotics before surgery.

Higher risk of liver cancer seen in women with intrahepatic cholestasis of pregnancy

Higher risk of liver cancer seen in women with intrahepatic cholestasis of pregnancy

Women with intrahepatic cholestasis of pregnancy (ICP) are at increased risk of hepatobiliary cancer.

Cancer risk linked to incidence of intrahepatic cholestasis of pregnancy

By

The risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is increased in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

Tenofovir may reduce risk of liver cancer in patients with HBV infection

Tenofovir may reduce risk of liver cancer in patients with HBV infection

Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.

Livers donated after cardiac death safe for use by liver cancer patients

By

Livers donated to cancer patients by individuals that died of cardiac death do not yield outcomes worse than those donated by people dying from brain death.

Hepatitis virus variations responsible for variations in liver cancer

By

Significant clinical variations have been identified among patients with hepatocellular carcinoma (HCC).

Livers donated after cardiac death safe for patients with liver cancer

Livers donated after cardiac death safe for patients with liver cancer

Patients with liver cancer have the same positive outcomes using organs donated by patients who died as a result of cardiac death.

Liver-sparing surgery may increase survival in patients with liver cancer

By

A surgical approach in which less than one lobe of the liver is removed in a patient undergoing resection for liver cancer is linked to lowered mortality and complication rates, according to new study results.

More alcohol consumption increases risk of liver cancer, but coffee is protective

More alcohol consumption increases risk of liver cancer, but coffee is protective

The amount of alcohol a person has to drink to risk developing liver cancer has been narrowed down.

Novel tool predicts postoperative liver cancer recurrence after transplant

By

The risk of disease recurrence in liver cancer patients who have undergone a liver transplant can now be more accurately calculated, thanks to new tool.

New imaging system may cut radiation exposure for liver cancer patients

By

An interventional x-ray guidance device approved by the U.S. Food and Drug Administration in 2013 may have the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.

New device may reduce radiation exposure to patients with liver cancer

New device may reduce radiation exposure to patients with liver cancer

AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer.

Antimicrobial agent triclosan, used in soaps and detergents, may cause cancer

Antimicrobial agent triclosan, used in soaps and detergents, may cause cancer

Triclosan, a popular antimicrobial agent in soaps, detergents, and plastics, has been found to promote liver cancer in mice.

Useful markers predict response to chemotherapy in patients with liver cancer

By

Liver tumor cells do not respond to sorafenib if they have a less differentiated phenotype, known as the mesenchymal type, and express CD44, according to a new study.

Improved survival for inoperative liver cancer through a combined therapy

By

Patients that have inoperable advanced hepatocellular carcinoma (HCC) may live significantly longer by receiving a combined therapy, according to recent trial results.

Everolimus does not improve overall survival of advanced liver cancer

By

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs